8:00 AM ET
8-K
M&A Deal
Valion Bio M&A Deal Update
Valion Bio has received unsolicited acquisition inquiries from third parties regarding its wholly owned CDMO subsidiary, Velocity Bioworks. The company has retained an investment bank to evaluate strategic options, including a potential sale, while prioritizing the retention of manufacturing rights for its lead drug candidate, Entolimod.